
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Tablets prepared from mefanamic acid spherical crystals were shown to exhibit better physical properties than those made from mefenamic powder.






